Jan Martin Berke

Jan Martin Berke, PhD has extensive experience in the pharmaceutical industry, with a focus on infectious diseases and haematology research and development. Jan Martin is currently the Director Biosciences Haematology Research & Development at Acerta Pharma B.V. (A member of the AstraZeneca Group) since 2023. Prior to this, they worked at The Janssen Pharmaceutical Companies of Johnson & Johnson, where they held various roles including Director Infectious Diseases Translational Discovery, Associate Scientific Director, Principal Scientist, and Senior Scientist. Jan Martin also worked at Tibotec BVBA as a Scientist and as a Scientist (PostDoc). Jan Martin Berke's research contributions include developing assays and conducting clinical trials for the treatment of hepatitis B virus and hepatitis C virus.

Jan Martin Berke, PhD received a Diploma (M.Sc.) in Cell Biology, Zoology, and Toxicology from Kiel University between 1998 and 2003. Jan Martin then pursued a Ph.D. in Cell Biology and Molecular Virology at The University of Freiburg from 2003 to 2007. Additionally, between 2005 and 2007, they worked as a Ph.D. student in Cell Biology and Molecular Virology at the Centre Hospitalier Universitaire Vaudois.